{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:35:33Z","timestamp":1648607733157},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T00:00:00Z","timestamp":1474588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Reumatologia (English Edition)"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.rbre.2016.09.007","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T08:08:26Z","timestamp":1476950906000},"page":"385-391","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab"],"prefix":"10.1016","volume":"57","author":[{"given":"Daniela","family":"Viecceli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Pires","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laiana","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Alegretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano Kohler","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Lucas","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claiton Viegas","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbre.2016.09.007_bib0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.0105-2896.2005.00245.x","article-title":"Rheumatoid arthritis","volume":"204","author":"Goronzy","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.rbre.2016.09.007_bib0180","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/07853890701477546","article-title":"Rheumatoid arthritis and the complement system","volume":"39","author":"Okroj","year":"2007","journal-title":"Ann Med"},{"key":"10.1016\/j.rbre.2016.09.007_bib0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","article-title":"Membrane complement regulatory proteins","volume":"118","author":"Kim","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.rbre.2016.09.007_bib0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0195","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0200","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rbre.2016.09.007_bib0205","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0210","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2016.09.007_bib0215","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2016.09.007_bib0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.rbre.2016.09.007_bib0225","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2007.02.004","article-title":"What is the role of rituximab in the treatment of rheumatoid arthritis","volume":"6","author":"Atzeni","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rbre.2016.09.007_bib0230","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","article-title":"Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE","volume":"71","author":"Tak","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2016.09.007_bib0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2016.09.007_bib0240","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2016.09.007_bib0245","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2016.09.007_bib0250","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/art.24035","article-title":"Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders","volume":"58","author":"Thurlings","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0255","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0260","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ard.2010.135376","article-title":"The need for personalised medicine for rheumatoid arthritis","volume":"70","author":"Isaacs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2016.09.007_bib0270","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.rbre.2016.09.007_bib0275","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.rbre.2016.09.007_bib0280","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1349-7006.2006.00139.x","article-title":"Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab","volume":"97","author":"Terui","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.rbre.2016.09.007_bib0285","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-08-1685","article-title":"In vivo model of follicular lymphoma resistant to rituximab","volume":"15","author":"Dalle","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rbre.2016.09.007_bib0290","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1590\/S0482-50042013000200004","article-title":"Diretrizes para o tratamento da artrite reumatoide","volume":"53","author":"Mota","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.rbre.2016.09.007_bib0295","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0300","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2016.09.007_bib0305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cellimm.2010.07.013","article-title":"Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients","volume":"265","author":"Alegretti","year":"2010","journal-title":"Cell Immunol"},{"key":"10.1016\/j.rbre.2016.09.007_bib0310","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12032-009-9278-9","article-title":"Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma","volume":"27","author":"Dzietczenia","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.rbre.2016.09.007_bib0315","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","article-title":"In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab","volume":"67","author":"Macor","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.rbre.2016.09.007_bib0320","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-10-3016","article-title":"Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis","volume":"71","author":"Hu","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.rbre.2016.09.007_bib0325","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/eji.200425920","article-title":"Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59","volume":"35","author":"Ziller","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.rbre.2016.09.007_bib0330","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/mt.2012.212","article-title":"Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques","volume":"21","author":"Beyer","year":"2013","journal-title":"Mol Ther"}],"container-title":["Revista Brasileira de Reumatologia (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255502116300748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255502116300748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T20:18:40Z","timestamp":1601151520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2255502116300748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S2255502116300748"],"URL":"https:\/\/doi.org\/10.1016\/j.rbre.2016.09.007","relation":{},"ISSN":["2255-5021"],"issn-type":[{"value":"2255-5021","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Reumatologia (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbre.2016.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rbr.2016.07.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}